Henry Schein (NASDAQ:HSIC) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Henry Schein (NASDAQ:HSIC) from a hold rating to a buy rating in a report issued on Saturday.

A number of other research firms have also issued reports on HSIC. BTIG Research upgraded Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Thursday, June 11th. Mizuho cut their target price on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Piper Sandler lifted their target price on Henry Schein from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Henry Schein in a research report on Monday, May 4th. Finally, Morgan Stanley reissued an “underweight” rating and issued a $64.00 price target (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Eight analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $89.36.

Henry Schein Stock Up 0.7%

Henry Schein stock opened at $85.75 on Friday. Henry Schein has a 1-year low of $61.94 and a 1-year high of $89.34. The firm has a market capitalization of $9.77 billion, a price-to-earnings ratio of 25.91, a P/E/G ratio of 1.65 and a beta of 0.81. The company has a current ratio of 1.36, a quick ratio of 0.75 and a debt-to-equity ratio of 0.59. The firm has a 50 day simple moving average of $82.19 and a 200 day simple moving average of $78.28.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. The business had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, analysts predict that Henry Schein will post 5.32 earnings per share for the current year.

Insider Activity

In other Henry Schein news, Director William K. Daniel acquired 10,000 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the transaction, the director owned 20,000 shares of the company’s stock, valued at approximately $1,383,800. This represents a 100.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.89% of the company’s stock.

Hedge Funds Weigh In On Henry Schein

A number of institutional investors have recently added to or reduced their stakes in the business. Tudor Investment Corp ET AL purchased a new position in shares of Henry Schein during the third quarter worth about $15,375,000. Heartland Advisors Inc. bought a new position in shares of Henry Schein in the fourth quarter worth approximately $9,070,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Henry Schein by 15.8% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 115,279 shares of the company’s stock valued at $8,856,000 after purchasing an additional 15,765 shares in the last quarter. Jefferies Financial Group Inc. raised its stake in Henry Schein by 365.6% in the fourth quarter. Jefferies Financial Group Inc. now owns 41,903 shares of the company’s stock valued at $3,167,000 after purchasing an additional 32,903 shares in the last quarter. Finally, K.J. Harrison & Partners Inc bought a new stake in Henry Schein during the first quarter valued at approximately $1,253,000. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.